Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon (Nasdaq: ANNX) has granted stock options to seven new non-executive employees under its 2022 Employment Inducement Award Plan. The grants, approved on November 12, 2024, comply with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase 495,000 shares of common stock at an exercise price of $6.12 per share, matching the closing price on November 15, 2024. The options have a ten-year term and vest over 4 years, with 25% vesting after the first year and 1/48th monthly thereafter, contingent on continued employment.
Annexon (Nasdaq: ANNX) ha concesso opzioni per azioni a sette nuovi dipendenti non esecutivi nell'ambito del suo Piano di Induzione all'Occupazione 2022. Le concessioni, approvate il 12 novembre 2024, sono in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). I dipendenti hanno ricevuto opzioni per acquistare 495.000 azioni ordinarie a un prezzo di esercizio di $6.12 per azione, pari al prezzo di chiusura del 15 novembre 2024. Le opzioni hanno una durata di dieci anni e maturano su un periodo di 4 anni, con il 25% che matura dopo il primo anno e 1/48 al mese successivamente, a condizione di continuare a essere impiegati.
Annexon (Nasdaq: ANNX) ha otorgado opciones sobre acciones a siete nuevos empleados no ejecutivos bajo su Plan de Inducción de Empleo 2022. Las concesiones, aprobadas el 12 de noviembre de 2024, cumplen con la Regla de Cotización de Nasdaq 5635(c)(4). Los empleados recibieron opciones para comprar 495,000 acciones comunes a un precio de ejercicio de $6.12 por acción, igual al precio de cierre del 15 de noviembre de 2024. Las opciones tienen un plazo de diez años y maduran durante 4 años, con el 25% madurando después del primer año y 1/48 mensual a partir de entonces, condicionado a la continuación del empleo.
Annexon (Nasdaq: ANNX)는 2022 고용 유인 상금 제도에 따라 7명의 새로운 비상임직원에게 주식 매수 선택권을 부여했습니다. 이 부여는 2024년 11월 12일에 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)을 준수합니다. 직원들은 495,000주를 $6.12의 행사가로 매입할 수 있는 옵션을 받았으며, 이는 2024년 11월 15일의 종가와 일치합니다. 이 옵션은 10년의 기간을 가지며, 4년 동안 분할 지급되며, 첫 해에 25%가 지급되고 이후 매달 1/48씩 지급됩니다. 계속 고용될 경우에 따른 조건입니다.
Annexon (Nasdaq: ANNX) a accordé des options d'achat d'actions à sept nouveaux employés non exécutifs dans le cadre de son Plan d'Induction à l'Emploi 2022. Les attributions, approuvées le 12 novembre 2024, sont conformes à la règle de cotation Nasdaq 5635(c)(4). Les employés ont reçu des options pour acheter 495,000 actions ordinaires à un prix d'exercice de $6.12 par action, correspondant au prix de clôture du 15 novembre 2024. Les options ont une durée de dix ans et deviennent acquises sur 4 ans, avec 25% devenant acquis après la première année et 1/48 mensuel ensuite, sous condition de continuation de l'emploi.
Annexon (Nasdaq: ANNX) hat sieben neuen Nicht-Exekutiv-Mitarbeitern im Rahmen seines Beschäftigungsanreizplans 2022 Aktienoptionen gewährt. Die Gewährungen, die am 12. November 2024 genehmigt wurden, entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die Mitarbeiter erhielten Optionen zum Kauf von 495.000 Stammaktien zu einem Ausübungspreis von $6.12 pro Aktie, was dem Schlusskurs vom 15. November 2024 entspricht. Die Optionen haben eine Laufzeit von zehn Jahren und erwerben sich über einen Zeitraum von 4 Jahren, wobei 25 % nach dem ersten Jahr und danach monatlich 1/48 erworben werden, abhängig von der Fortsetzung des Beschäftigungsverhältnisses.
- Stock options grant demonstrates ability to attract new talent
- Four-year vesting schedule helps retain employees long-term
- Potential shareholder dilution from 495,000 new stock options
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on November 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 495,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing classical complement-driven neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. When they thrive, we thrive. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
How many shares were granted in Annexon's (ANNX) November 2024 employee inducement grants?
What is the exercise price for Annexon's (ANNX) November 2024 inducement stock options?
What is the vesting schedule for Annexon's (ANNX) November 2024 inducement grants?
